Patents Assigned to BEYONDBIO INC.
  • Process for preparing pyrimidinyl bipyridine compound and intermediate therefor
    Patent number: 12371418
    Abstract: Provided are a process for preparing a pyrimidinyl bipyridine compound having high purity with high yields without using high-cost silica gels, and an intermediate used therein.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: July 29, 2025
    Assignee: BEYONDBIO INC.
    Inventors: Changhee Min, Ki-Hyun Nah, Hoon Young Son
  • PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR
    Publication number: 20220324839
    Abstract: Provided are a process for preparing a pyrimidinyl bipyridine compound having high purity with high yields without using high-cost silica gels, and an intermediate used therein.
    Type: Application
    Filed: September 4, 2020
    Publication date: October 13, 2022
    Applicant: BEYONDBIO INC.
    Inventors: Changhee MIN, Ki-Hyun NAH, Hoon Young SON
  • HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20200190062
    Abstract: A novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition containing the compound as an effective ingredient are disclosed. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Applicant: BEYONDBIO INC.
    Inventors: Changhee MIN, Byungkyu OH, Yongeun KIM, Changmin PARK
  • Heterocyclic compound and pharmaceutical composition comprising same
    Patent number: 10611754
    Abstract: The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: April 7, 2020
    Assignee: BEYONDBIO INC.
    Inventors: Changhee Min, Byungkyu Oh, Yongeun Kim, Changmin Park
  • HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20190135786
    Abstract: The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 9, 2019
    Applicant: BEYONDBIO INC.
    Inventors: Changhee Min, Byungkyu Oh, Yongeun Kim, Changmin Park
  • Heterocyclic compound and pharmaceutical composition comprising same
    Patent number: 10227328
    Abstract: The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: March 12, 2019
    Assignee: BEYONDBIO INC.
    Inventors: Changhee Min, Byungkyu Oh, Yongeun Kim, Changmin Park
  • HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20180273510
    Abstract: The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.
    Type: Application
    Filed: February 2, 2016
    Publication date: September 27, 2018
    Applicant: BEYONDBIO INC.
    Inventors: Changhee MIN, Byungkyu OH, Yongeun KIM, Changmin PARK